Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

Novo Nordisk A/S

+ Add to Watchlist


56.8500 USD 0.1500 0.26%

As of 14:01:40 ET on 05/27/2015.

Snapshot for Novo Nordisk A/S (NONOF)

Open: 57.4250 Day's Range: 56.7500 - 57.6000 Volume: 5,545
Previous Close: 57.0000 52wk Range: 41.7000 - 58.4500 1-Yr Rtn: +31.06%

Stock Chart for NONOF

No chart data available.
  • NONOF:US 57.6000
  • 1D
  • 1M
  • 1Y
Interactive NONOF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NONOF

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 30.3099
Relative P/E vs. SPX -
Earnings Per Share (DKK) (ttm) -
Est. EPS (DKK) (12/2015) 12.8290
Est. PEG Ratio 2.0055
Market Cap (M USD) 149,625.81
Shares Outstanding (M) 2,062.56
30 Day Average Volume 10,613
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.28%
Cash Dividend (DKK) 5.0000
Dividend Ex-Date 03/20/2015
5 Year Dividend Growth 22.09%
Next Earnings Announcement 08/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NONOF

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for NONOF

Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.

Lars Rebien SorensenPresident/CEOJesper BrandgaardChief Financial Officer
Lars Fruergaard JorgensenExec VP:Corp DevelopmentJakob RiisExec VP: Marketing,Medic Affers&Stakehold ENG
More Company Profile & Key Executives for NONOF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil